| View |
|
BR-1280
|
Atezolizumab
|
Tecentriq
|
60 mg/mL (1.2 g/20 mL)
|
Concentrate for Solution for
Infusion
|
-
|
Roche Diagnostics GmbH
|
Germany
|
Monitored Release (Variation)
|
22 February 2023
|
22 February 2028
|
| View |
|
BR-1282
|
Eptacog alfa activated
|
NovoSeven RT
|
1 mg/vial (50KIU/vial)
|
Powder And Solvent For Solution For Injection
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
01 August 2023
|
25 July 2028
|
| View |
|
BR-1284
|
Isophane Insulin (Recombinant DNA)
|
Humulin N
|
100 Units/mL
|
Suspension for Injection (SC)
|
-
|
Lilly France S.A.S.
|
France
|
Renewal
|
11 October 2022
|
31 October 2027
|
| View |
|
BR-1290
|
Inactivated Poliomyelitis Vaccine (Types 1, 2 And 3)
|
Poliovac
|
0.5 mL
|
Suspension For Injection (IM/SC)
|
-
|
Serum Institute of India Private Limited
|
India
|
Initial (Variation)
|
09 February 2023
|
09 February 2028
|
| View |
|
BR-1296
|
Dulaglutide
|
Trulicity
|
0.75 mg/0.5 mL
|
Solution For Injection
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1297_PI_01.pdf
|
BR-1297
|
Dulaglutide
|
Trulicity
|
1.5 mg/0.5 mL
|
Solution For Injection
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1299_PI_01.pdf
|
BR-1299
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
BR-1300_PI_01.pdf
|
BR-1300
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
|
BR-1303
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 720
|
720 ELISA units/0.5 mL
|
Suspension for Injection (IM)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Initial (Variation)
|
28 June 2024
|
28 June 2029
|
| View |
|
BR-1304
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 1440
|
1440 ELISA units/mL
|
Suspension For Injection (IM)
|
Vaccine
|
GlazoSmithKlineBiologicals SA
|
Belgium
|
Renewal
|
31 May 2024
|
14 August 2029
|
| View |
|
BR-1308
|
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) [See formulation]
|
Prevenar 13
|
0.5 mL per dose
|
Suspension For Im Injection
|
Vaccine
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Renewal
|
07 October 2024
|
05 December 2029
|
| View |
BR-1311_PI_01.pdf
|
BR-1311
|
Ustekinumab
|
Stelara
|
130mg/26mL
|
Concentrate for Solution For Infusion (Iv)
|
-
|
Cilag AG
|
Switzerland
|
-
|
02 April 2020
|
02 April 2025
|
| View |
|
BR-1315
|
Pneumococcal Polysaccharide Vaccine, Polyvalent
|
Pneumovax 23
|
Each dose (0.5 mL) contains 25 mcg of each polysaccharide type (types 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) dissolved in isotonic saline solution containing 0.25% phenol as a preservative.
|
Solution for Injection (I.M./ S.C.)
|
-
|
MSD International GmbH T/A MSD Ireland (Carlow)
|
Ireland
|
-
|
02 April 2020
|
02 April 2025
|
| View |
|
BR-1316
|
Trastuzumab
|
Herzuma
|
150mg
|
Powder for Concentrate Solution For Infusion (IV)
|
-
|
Celltrion Inc, Republic of Korea
|
Korea
|
-
|
03 April 2020
|
03 April 2025
|
| View |
|
BR-1317
|
Trastuzumab
|
HERZUMA
|
440mg
|
Powder for Concentrate for Solution fro Infusion (IV)
|
-
|
Celltrion Pharm, Inc.
|
Korea
|
-
|
03 April 2020
|
03 April 2025
|
| View |
BR-1318_PI_01.pdf
|
BR-1318
|
Follitropin Alfa / Lutropin Alfa
|
Pergoveris
|
350 IU/150 IU (0.48mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A.
|
Italy
|
-
|
16 April 2020
|
16 April 2025
|
| View |
|
BR-1319
|
Follitropin alfa / Lutropin alfa
|
Pergoveris
|
450 IU/225 IU (0.72 mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A
|
Italy
|
Variation
|
11 June 2021
|
16 April 2025
|
| View |
|
BR-1320
|
Follitropin alfa / Lutropin alfa
|
Pergoveris
|
900 IU/450 IU (1.44 mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A.
|
Italy
|
Variation
|
11 June 2021
|
16 April 2025
|
| View |
BR-1321_PI_01.pdf
|
BR-1321
|
Botulinum Toxin Type A
|
Nabota
|
200 Units
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
-
|
Daewoong Pharmaceutical Co., Ltd.
|
Korea
|
Monitored Release
|
16 June 2020
|
16 June 2025
|
| View |
BR-1323_PI_01.pdf
|
BR-1323
|
Adalimumab
|
Humira
|
20mg/0.2mL
|
Solution For Injection (SC)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
monitored Release
|
24 June 2020
|
24 June 2025
|